EVAX Quote, Financials, Valuation and Earnings

Ascendis Pharma AS has a net margin of -64.14% compared to Evaxion AS's net margin of -93.73%. Evaxion AS's return on equity of -- beat Ascendis Pharma AS's return on equity of -880.05%.

Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 378.34%. On the other hand Ascendis Pharma AS has an analysts' consensus of $229.05 which suggests that it could grow by 34.11%. Given that Evaxion AS has higher upside potential than Ascendis Pharma AS, analysts believe Evaxion AS is more attractive than Ascendis Pharma AS.

Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.366, suggesting its less volatile than the S&P 500 by 63.446%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

Evaxion AS quarterly revenues are $3M, which are smaller than Ascendis Pharma AS quarterly revenues of $106.2M. Evaxion AS's net income of -$1.6M is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, Evaxion AS's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 1.83x versus 25.44x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of -64.14% compared to Evaxion AS's net margin of --. Evaxion AS's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 378.34%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1577%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Evaxion AS, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Evaxion AS.

Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.210, suggesting its more volatile than the S&P 500 by 21.022%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Evaxion AS quarterly revenues are $3M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Evaxion AS's net income of -$1.6M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Evaxion AS's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 1.83x versus 1.11x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -64.14% compared to Evaxion AS's net margin of --. Evaxion AS's return on equity of -- beat DBV Technologies SA's return on equity of --.

Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 378.34%. On the other hand DBV Technologies SA has an analysts' consensus of $14.76 which suggests that it could grow by 62.18%. Given that Evaxion AS has higher upside potential than DBV Technologies SA, analysts believe Evaxion AS is more attractive than DBV Technologies SA.

Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.624, suggesting its less volatile than the S&P 500 by 162.448%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Evaxion AS quarterly revenues are $3M, which are larger than DBV Technologies SA quarterly revenues of --. Evaxion AS's net income of -$1.6M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Evaxion AS's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 1.83x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -64.14% compared to Evaxion AS's net margin of 37.18%. Evaxion AS's return on equity of -- beat Novo Nordisk AS's return on equity of 84.88%.

Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 378.34%. On the other hand Novo Nordisk AS has an analysts' consensus of $91.54 which suggests that it could grow by 14.61%. Given that Evaxion AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion AS is more attractive than Novo Nordisk AS.

Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.759%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.08% to investors and pays a quarterly dividend of $1.14 per share. Evaxion AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evaxion AS quarterly revenues are $3M, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Evaxion AS's net income of -$1.6M is lower than Novo Nordisk AS's net income of $4.1B. Notably, Evaxion AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 23.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 1.83x versus 8.16x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.